Skip to main content
Top
Published in: BMC Women's Health 1/2019

Open Access 01-12-2019 | Vulvovaginal Candidiasis | Research article

Current patient perspectives of vulvovaginal candidiasis: incidence, symptoms, management and post-treatment outcomes

Authors: Junko Yano, Jack D. Sobel, Paul Nyirjesy, Ryan Sobel, Valerie L. Williams, Qingzhao Yu, Mairi C. Noverr, Paul L. Fidel Jr

Published in: BMC Women's Health | Issue 1/2019

Login to get access

Abstract

Background

Vulvovaginal candidiasis (VVC) is a common infection affecting women worldwide. Reports of patterns/risk factors/trends for episodic/recurrent VVC (RVVC) are largely outdated. The purpose of this study was to obtain current patient perspectives of several aspects of VVC/RVVC.

Methods

Business cards containing on-line survey information were distributed to healthy volunteers and patients seeking standard, elective, or referral gynecologic care in university-affiliated Obstetrics/Gynecology clinics. The internet-based questionnaire was completed by 284 non-pregnant women (78% Caucasian, 14% African American, 8% Asian).

Results

The majority of the participants (78%) indicated a history of VVC with 34% defined as having RVVC. The most common signs/symptoms experienced were itching, burning and redness with similar ranking of symptoms among VVC and RVVC patients. Among risk factors, antibiotic use ranked highest followed by intercourse, humid weather and use of feminine hygiene products. A high number of respondents noted ‘no known cause’ (idiopathic episodes) that was surprisingly similar among women with a history of either VVC or RVVC. VVC/RVVC episodes reported were primarily physician-diagnosed (73%) with the remainder mostly reporting self-diagnosis and treating with over-the-counter (OTC) medications. Most physician-diagnosed attacks utilized a combination of pelvic examination and laboratory tests followed by prescribed antifungals. Physician-treated cases achieved a higher level of symptom relief (84%) compared to those who self-medicated (57%). The majority of women with RVVC (71%) required continual or long-term antifungal medication as maintenance therapy to control symptoms.

Conclusions

Current patient perspectives closely reflect historically documented estimates of VVC/RVVC prevalence and trends regarding symptomatology, disease management and post-treatment outcomes.
Appendix
Available only for authorised users
Literature
1.
go back to reference Sobel JD. Epidemiology and pathogenesis of recurrent vulvovaginal candidiasis. Am J Obstet Gynecol. 1985;152(7 Pt 2):924–35.CrossRef Sobel JD. Epidemiology and pathogenesis of recurrent vulvovaginal candidiasis. Am J Obstet Gynecol. 1985;152(7 Pt 2):924–35.CrossRef
2.
go back to reference Sobel JD, Faro S, Force RW, Foxman B, Ledger WJ, Nyirjesy PR, et al. Vulvovaginal candidiasis: epidemiologic, diagnostic, and therapeutic considerations. Am J Obstet Gynecol. 1998;178(2):203–11.CrossRef Sobel JD, Faro S, Force RW, Foxman B, Ledger WJ, Nyirjesy PR, et al. Vulvovaginal candidiasis: epidemiologic, diagnostic, and therapeutic considerations. Am J Obstet Gynecol. 1998;178(2):203–11.CrossRef
3.
go back to reference Fidel PL Jr, Barousse M, Espinosa T, Ficarra M, Sturtevant J, Martin DH, et al. An intravaginal live Candida challenge in humans leads to new hypotheses for the immunopathogenesis of vulvovaginal candidiasis. Infect Immun. 2004;72:2939–46.CrossRef Fidel PL Jr, Barousse M, Espinosa T, Ficarra M, Sturtevant J, Martin DH, et al. An intravaginal live Candida challenge in humans leads to new hypotheses for the immunopathogenesis of vulvovaginal candidiasis. Infect Immun. 2004;72:2939–46.CrossRef
4.
go back to reference Sobel JD. Pathogenesis and treatment of recurrent vulvovaginal candidiasis. Clin Infect Dis. 1992;14(Suppl 1):S148–53.CrossRef Sobel JD. Pathogenesis and treatment of recurrent vulvovaginal candidiasis. Clin Infect Dis. 1992;14(Suppl 1):S148–53.CrossRef
6.
go back to reference Achkar JM, Fries BC. Candida infections of the genitourinary tract. Clin Microbiol Rev. 2010;23(2):253–73.CrossRef Achkar JM, Fries BC. Candida infections of the genitourinary tract. Clin Microbiol Rev. 2010;23(2):253–73.CrossRef
7.
go back to reference Denning DW, Kneale M, Sobel JD, Rautemaa-Richardson R. Global burden of recurrent vulvovaginal candidiasis: a systematic review. Lancet Infect Dis. 2018;18(11):e339–e47.CrossRef Denning DW, Kneale M, Sobel JD, Rautemaa-Richardson R. Global burden of recurrent vulvovaginal candidiasis: a systematic review. Lancet Infect Dis. 2018;18(11):e339–e47.CrossRef
8.
go back to reference Blostein F, Levin-Sparenberg E, Wagner J, Foxman B. Recurrent vulvovaginal candidiasis. Ann Epidemiol. 2017;27(9):575–82.CrossRef Blostein F, Levin-Sparenberg E, Wagner J, Foxman B. Recurrent vulvovaginal candidiasis. Ann Epidemiol. 2017;27(9):575–82.CrossRef
9.
10.
go back to reference Fidel PL Jr. History and new insights into host defense against vaginal candidiasis. Trends Microbiol. 2004;12(5):220–7.CrossRef Fidel PL Jr. History and new insights into host defense against vaginal candidiasis. Trends Microbiol. 2004;12(5):220–7.CrossRef
11.
go back to reference Peters BM, Yano J, Noverr MC, Fidel PL Jr. Candida vaginitis: when opportunism knocks, the host responds. PLoS Pathog. 2014;10(4):e1003965.CrossRef Peters BM, Yano J, Noverr MC, Fidel PL Jr. Candida vaginitis: when opportunism knocks, the host responds. PLoS Pathog. 2014;10(4):e1003965.CrossRef
12.
go back to reference Yano J, Noverr MC, Fidel PL Jr. Cytokines in the host response to Candida vaginitis: identifying a role for non-classical immune mediators, S100 alarmins. Cytokine. 2012;58(1):118–28.CrossRef Yano J, Noverr MC, Fidel PL Jr. Cytokines in the host response to Candida vaginitis: identifying a role for non-classical immune mediators, S100 alarmins. Cytokine. 2012;58(1):118–28.CrossRef
13.
go back to reference Cassone A. Vulvovaginal Candida albicans infections: pathogenesis, immunity and vaccine prospects. BJOG. 2015;122(6):785–94.CrossRef Cassone A. Vulvovaginal Candida albicans infections: pathogenesis, immunity and vaccine prospects. BJOG. 2015;122(6):785–94.CrossRef
14.
go back to reference Yano J, Noverr MC, Fidel PL Jr. Vaginal heparan sulfate linked to neutrophil dysfunction in the acute inflammatory response associated with experimental vulvovaginal candidiasis. mBio. 2017;8(2):e00211–7.CrossRef Yano J, Noverr MC, Fidel PL Jr. Vaginal heparan sulfate linked to neutrophil dysfunction in the acute inflammatory response associated with experimental vulvovaginal candidiasis. mBio. 2017;8(2):e00211–7.CrossRef
15.
go back to reference Hurley R, De Louvois J. Candida vaginitis. Postgrad Med J. 1979;55(647):645–7.CrossRef Hurley R, De Louvois J. Candida vaginitis. Postgrad Med J. 1979;55(647):645–7.CrossRef
16.
go back to reference Geiger AM, Foxman B, Gillespie BW. The epidemiology of vulvovaginal candidiasis among university students. Am J Public Health. 1995;85(8 Pt 1):1146–8.CrossRef Geiger AM, Foxman B, Gillespie BW. The epidemiology of vulvovaginal candidiasis among university students. Am J Public Health. 1995;85(8 Pt 1):1146–8.CrossRef
17.
go back to reference Berg AO, Heidrich FE, Fihn SD, Bergman JJ, Wood RW, Stamm WE, et al. Establishing the cause of genitourinary symptoms in women in a family practice. Comparison of clinical examination and comprehensive microbiology. JAMA. 1984;251(5):620–5.CrossRef Berg AO, Heidrich FE, Fihn SD, Bergman JJ, Wood RW, Stamm WE, et al. Establishing the cause of genitourinary symptoms in women in a family practice. Comparison of clinical examination and comprehensive microbiology. JAMA. 1984;251(5):620–5.CrossRef
18.
go back to reference Horowitz BJ, Edelstein SW, Lippman L. Sexual transmission of Candida. Obstet Gynecol. 1987;69(6):883–6.PubMed Horowitz BJ, Edelstein SW, Lippman L. Sexual transmission of Candida. Obstet Gynecol. 1987;69(6):883–6.PubMed
19.
go back to reference Anderson MR, Klink K, Cohrssen A. Evaluation of vaginal complaints. JAMA. 2004;291(11):1368–79.CrossRef Anderson MR, Klink K, Cohrssen A. Evaluation of vaginal complaints. JAMA. 2004;291(11):1368–79.CrossRef
20.
go back to reference Foxman B, Marsh JV, Gillespie B, Sobel JD. Frequency and response to vaginal symptoms among white and African American women: results of a random digit dialing survey. J Women's Health. 1998;7(9):1167–74.CrossRef Foxman B, Marsh JV, Gillespie B, Sobel JD. Frequency and response to vaginal symptoms among white and African American women: results of a random digit dialing survey. J Women's Health. 1998;7(9):1167–74.CrossRef
21.
go back to reference Fischer G, Bradford J. Vulvovaginal candidiasis in postmenopausal women: the role of hormone replacement therapy. J Low Genit Tract Dis. 2011;15(4):263–7.CrossRef Fischer G, Bradford J. Vulvovaginal candidiasis in postmenopausal women: the role of hormone replacement therapy. J Low Genit Tract Dis. 2011;15(4):263–7.CrossRef
22.
go back to reference Sobel JD, Kapernick PS, Zervos M, Reed BD, Hooton T, Soper D, et al. Treatment of complicated Candida vaginitis: comparison of single and sequential doses of fluconazole. Am J Obstet Gynecol. 2001;185(2):363–9.CrossRef Sobel JD, Kapernick PS, Zervos M, Reed BD, Hooton T, Soper D, et al. Treatment of complicated Candida vaginitis: comparison of single and sequential doses of fluconazole. Am J Obstet Gynecol. 2001;185(2):363–9.CrossRef
23.
go back to reference Reef SE, Levine WC, McNeil MM, Fisher-Hoch S, Holmberg SD, Duerr A, et al. Treatment options for vulvovaginal candidiasis, 1993. Clin Infect Dis. 1995;20(Suppl 1):S80–90.CrossRef Reef SE, Levine WC, McNeil MM, Fisher-Hoch S, Holmberg SD, Duerr A, et al. Treatment options for vulvovaginal candidiasis, 1993. Clin Infect Dis. 1995;20(Suppl 1):S80–90.CrossRef
24.
go back to reference Sobel JD, Wiesenfeld HC, Martens M, Danna P, Hooton TM, Rompalo A, et al. Maintenance fluconazole therapy for recurrent vulvovaginal candidiasis. N Engl J Med. 2004;351(9):876–83.CrossRef Sobel JD, Wiesenfeld HC, Martens M, Danna P, Hooton TM, Rompalo A, et al. Maintenance fluconazole therapy for recurrent vulvovaginal candidiasis. N Engl J Med. 2004;351(9):876–83.CrossRef
25.
go back to reference Farmer MA, Taylor AM, Bailey AL, Tuttle AH, MacIntyre LC, Milagrosa ZE, et al. Repeated vulvovaginal fungal infections cause persistent pain in a mouse model of vulvodynia. Sci Transl Med. 2011;3(101):101ra91.CrossRef Farmer MA, Taylor AM, Bailey AL, Tuttle AH, MacIntyre LC, Milagrosa ZE, et al. Repeated vulvovaginal fungal infections cause persistent pain in a mouse model of vulvodynia. Sci Transl Med. 2011;3(101):101ra91.CrossRef
26.
go back to reference Foxman B, Muraglia R, Dietz JP, Sobel JD, Wagner J. Prevalence of recurrent vulvovaginal candidiasis in 5 European countries and the United States: results from an internet panel survey. J Low Genit Tract Dis. 2013;17(3):340–5.CrossRef Foxman B, Muraglia R, Dietz JP, Sobel JD, Wagner J. Prevalence of recurrent vulvovaginal candidiasis in 5 European countries and the United States: results from an internet panel survey. J Low Genit Tract Dis. 2013;17(3):340–5.CrossRef
27.
go back to reference Geiger AM, Foxman B. Risk factors for vulvovaginal candidiasis: a case-control study among university students. Epidemiology. 1996;7(2):182–7.CrossRef Geiger AM, Foxman B. Risk factors for vulvovaginal candidiasis: a case-control study among university students. Epidemiology. 1996;7(2):182–7.CrossRef
28.
go back to reference de Leon EM, Jacober SJ, Sobel JD, Foxman B. Prevalence and risk factors for vaginal Candida colonization in women with type 1 and type 2 diabetes. BMC Infect Dis. 2002;2:1.CrossRef de Leon EM, Jacober SJ, Sobel JD, Foxman B. Prevalence and risk factors for vaginal Candida colonization in women with type 1 and type 2 diabetes. BMC Infect Dis. 2002;2:1.CrossRef
29.
go back to reference Drell T, Lillsaar T, Tummeleht L, Simm J, Aaspollu A, Vain E, et al. Characterization of the vaginal micro- and mycobiome in asymptomatic reproductive-age Estonian women. PLoS One. 2013;8(1):e54379.CrossRef Drell T, Lillsaar T, Tummeleht L, Simm J, Aaspollu A, Vain E, et al. Characterization of the vaginal micro- and mycobiome in asymptomatic reproductive-age Estonian women. PLoS One. 2013;8(1):e54379.CrossRef
30.
go back to reference Foxman B, Barlow R, D'Arcy H, Gillespie B, Sobel JD. Candida vaginitis: self-reported incidence and associated costs. Sex Transm Dis. 2000;27(4):230–5.CrossRef Foxman B, Barlow R, D'Arcy H, Gillespie B, Sobel JD. Candida vaginitis: self-reported incidence and associated costs. Sex Transm Dis. 2000;27(4):230–5.CrossRef
31.
go back to reference Geiger AM, Foxman B, Sobel JD. Chronic vulvovaginal candidiasis: characteristics of women with Candida albicans, C glabrata and no candida. Genitourin Med. 1995;71(5):304–7.PubMedPubMedCentral Geiger AM, Foxman B, Sobel JD. Chronic vulvovaginal candidiasis: characteristics of women with Candida albicans, C glabrata and no candida. Genitourin Med. 1995;71(5):304–7.PubMedPubMedCentral
32.
go back to reference Mintz JD, Martens MG. Prevalence of non-albicans Candida infections in women with recurrent vulvovaginal symptomatology. Adv Infect Dis. 2013;3(4):5. Mintz JD, Martens MG. Prevalence of non-albicans Candida infections in women with recurrent vulvovaginal symptomatology. Adv Infect Dis. 2013;3(4):5.
Metadata
Title
Current patient perspectives of vulvovaginal candidiasis: incidence, symptoms, management and post-treatment outcomes
Authors
Junko Yano
Jack D. Sobel
Paul Nyirjesy
Ryan Sobel
Valerie L. Williams
Qingzhao Yu
Mairi C. Noverr
Paul L. Fidel Jr
Publication date
01-12-2019
Publisher
BioMed Central
Published in
BMC Women's Health / Issue 1/2019
Electronic ISSN: 1472-6874
DOI
https://doi.org/10.1186/s12905-019-0748-8

Other articles of this Issue 1/2019

BMC Women's Health 1/2019 Go to the issue